Cite
HARVARD Citation
Fazio, F. et al. (2022). Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group. EJHaem. 3 (1), pp. 121-128. [Online].